Two structurally different forms of activated human Factor IX (Factor IXa alpha and IXa beta) have been previously reported to have essentially identical clotting activity in vitro. Although it has been shown that activated Factor IX Chapel Hill, an abnormal Factor IX isolated from the plasma of a patient with mild hemophilia B, and normal Factor IXa alpha are structurally very similar, the clotting activity of activated Factor IX Chapel Hill is much lower (approximately fivefold) than that of normal Factor IXa beta. In the present study we have prepared activated Factor IX by incubating human Factor IX with calcium and Russell's viper venom covalently bound to agarose. Fractionation of the activated Factor IX by high-performance liquid chromatography demonstrated the presence of both Factors IXa alpha and IXa beta. On the basis of active site concentration, determined by titration with antithrombin III, the clotting activities of activated Factor IX Chapel Hill and IXa alpha were similar, but both activities were less than 20% of the clotting activity of Factor IXa beta. Activated Factor IX activity was also measured in the absence of calcium, phospholipid, and Factor VIII, by determination of the rate of Factor X activation in the presence of polylysine. In the presence of polylysine, the rates of Factor X activation by activated Factor IX Chapel Hill, Factor IXa alpha, and Factor IXa beta were essentially identical. We conclude that the clotting activity of activated Factor IX Chapel Hill is reduced when compared with that of Factor IXa beta but essentially normal when compared with that of Factor IXa alpha.
M J Griffith, L Breitkreutz, H Trapp, E Briet, C M Noyes, R L Lundblad, H R Roberts
Title and authors | Publication | Year |
---|---|---|
Blood coagulation factor IX: structural insights impacting hemophilia B therapy
Bos MH, van Diest RE, Monroe DM |
Blood | 2024 |
Protease propeptide structures, mechanisms of activation, and functions
L Boon, E Ugarte-Berzal, J Vandooren, G Opdenakker |
Critical Reviews in Biochemistry and Molecular Biology | 2020 |
A candidate activation pathway for coagulation factor VII
TM Misenheimer, KT Kumfer, BE Bates, ER Nettesheim, BS Schwartz |
Biochemical Journal | 2019 |
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity
E Perot, N Enjolras, SL Quellec, A Indalecio, J Girard, C Negrier, Y Dargaud |
Thrombosis Research | 2015 |
Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo:
CY Kao, SJ Yang, MH Tao, YM Jeng, IS Yu, SW Lin |
Thrombosis and Haemostasis | 2013 |
Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor
JY Chang, P Chantrathammachart, DM Monroe, NS Key |
Thrombosis Research | 2012 |
Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction
B Sullenger, R Woodruff, DM Monroe |
The Journal of biological chemistry | 2012 |
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance
EC Nieves, N Manchanda |
The Journal of biological chemistry | 2010 |
Generation of a novel factor IX with augmented clotting activities in vitro and in vivo
CN Lin, CY Kao, CH Miao, N Hamaguchi, HL Wu, GY Shi, YL Liu, KA High, SW Lin |
Journal of Thrombosis and Haemostasis | 2010 |
FVII Dependent Coagulation Activation in Citrated Plasma by Polymer Hydrogels
BJ Casey, AM Behrens, JR Hess, ZJ Wu, BP Griffith, P Kofinas |
Biomacromolecules | 2010 |
Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV
T Gui, A Reheman, H Ni, PL Gross, F Yin, D Monroe, PE Monahan, DW Stafford |
Journal of Thrombosis and Haemostasis | 2009 |
The Factor IX γ-Carboxyglutamic Acid (Gla) Domain Is Involved in Interactions between Factor IX and Factor XIa
A Aktimur, MA Gabriel, D Gailani, JR Toomey |
The Journal of biological chemistry | 2002 |
Identification of Functionally Important Residues of the Epidermal Growth Factor-2 Domain of Factor IX by Alanine-scanning Mutagenesis: RESIDUES ASN 89 –GLY 93 ARE CRITICAL FOR BINDING FACTOR VIIIa
YJ Chang, HL Wu, N Hamaguchi, YC Hsu, SW Lin |
The Journal of biological chemistry | 2002 |
Pan Vascular Medicine
P Lanzer, EJ Topol |
2002 | |
Residues Y179 and H101 of a Hydrophobic Patch of Factor VII Are Involved in Activation by Factor Xa
J Jin, J Chang, DW Stafford, DL Straight |
Biochemistry | 2001 |
The Distinct Roles That Gln-192 and Glu-217 of Factor IX Play in Selectivity for Macromolecular Substrates and Inhibitors
YC Hsu, N Hamaguchi, YJ Chang, SW Lin |
Biochemistry | 2001 |
Protease Nexin-2/Amyloid β-Protein Precursor Regulates Factor VIIa and the Factor VIIa–Tissue Factor Complex
F Mahdi, A Rehemtulla, WE van Nostrand, SP Bajaj, AH Schmaier |
Thrombosis Research | 2000 |
An Arg/Ser Substitution in the Second Epidermal Growth Factor–Like Module of Factor IX Introduces an O-Linked Carbohydrate and Markedly Impairs Activation by Factor XIa and Factor VIIa/Tissue Factor and Catalytic Efficiency of Factor IXa
MS Hertzberg, SL Facey, PJ Hogg |
Blood | 1999 |
Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity
J Chang, J Jin, P Lollar, W Bode, H Brandstetter, N Hamaguchi, DL Straight, DW Stafford |
The Journal of biological chemistry | 1998 |
Nitrophorin-2: A Novel Mixed-Type Reversible Specific Inhibitor of the Intrinsic Factor-X Activating Complex
Y Zhang, JM Ribeiro, JA Guimarães, PN Walsh |
Biochemistry | 1998 |
Reduced levels of skeletal muscle Na + K + -ATPase in McArdle disease
RG Haller, T Clausen, J Vissing |
Neurology | 1998 |
Structural Integrity of the -Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa
PJ Larson, SA Stanfield-Oakley, WJ VanDusen, CK Kasper, KJ Smith, DM Monroe, KA High |
The Journal of biological chemistry | 1996 |
Protease Nexin-2/Amyloid β-Protein Precursor Inhibits Factor Xa in the Prothrombinase Complex
F Mahdi, WE van Nostrand, AH Schmaier |
The Journal of biological chemistry | 1995 |
Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme
PJ Lenting, H Maat, PP Clijsters, MJ Donath, JA van Mourik, K Mertens |
The Journal of biological chemistry | 1995 |
Enhanced Plasmin Inhibition by a Reactive Center Lysine Mutant of the Kunitz-type Protease Inhibitor Domain of the Amyloid β-Protein Precursor
WE van Nostrand, AH Schmaier, RS Siegel, SL Wagner, WC Raschke |
The Journal of biological chemistry | 1995 |
Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid β-protein precursor-like protein-2
WE van Nostrand, AH Schmaier, BR Neiditch, RS Siegel, WC Raschke, SS Sisodia, SL Wagner |
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology | 1994 |
Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes
M Kalafatis, NA Swords, MD Rand, KG Mann |
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | 1994 |
The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa
MM Fiore, PF Neuenschwander, JH Morrissey |
The Journal of biological chemistry | 1994 |
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa
AH Schmaier, LD Dahl, AJ Rozemuller, RA Roos, SL Wagner, R Chung, WE van Nostrand |
Journal of Clinical Investigation | 1993 |
Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources
JB Lefkowitz, DM Monroe, CK Kasper, HR Roberts |
American Journal of Hematology | 1993 |
Heparin binding to protein C inhibitor
CW Pratt, FC Church |
The Journal of biological chemistry | 1992 |
Blood clotting factor IX Nagoya 3: The molecular defect of zymogen activation caused by an arginine-145 to histidine substitution
K Suehiro, T Miyata, H Takeya, J Takamatsu, H Saito, M Murakawa, T Okamura, Y Niho, S Iwanaga |
Thrombosis Research | 1990 |
Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor
Y Komiyama, AH Pedersen, W Kisiel |
Biochemistry | 1990 |
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg")
HH Watzke, K Lechner, HR Roberts, SV Reddy, DJ Welsch, P Friedman, G Mahr, P Jagadeeswaran, DM Monroe, KA High |
The Journal of biological chemistry | 1990 |
Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain
DM McCord, DM Monroe, KJ Smith, HR Roberts |
The Journal of biological chemistry | 1990 |
Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules
SS Ahmad, R Rawala-Sheikh, DM Monroe, HR Roberts, PN Walsh |
The Journal of biological chemistry | 1990 |
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions
AH Pedersen, O Nordfang, F Norris, FC Wiberg, PM Christensen, KB Moeller, J Meidahl-Pedersen, TC Beck, K Norris, U Hedner |
The Journal of biological chemistry | 1990 |
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw
MB Liddell, DP Lillicrap, IR Peake, AL Bloom |
British Journal of Haematology | 1989 |
Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor
DS Telgt, BG Macik, DM McCord, DM Monroe, HR Roberts |
Thrombosis Research | 1989 |
A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver
VA Geddes, BF Bonniec, GV Louie, GD Brayer, AR Thompson, RT MacGillivray |
The Journal of biological chemistry | 1989 |
Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases
DM Monroe, GB Sherrill, HR Roberts |
Analytical Biochemistry | 1988 |
Comparison of lipid binding and kinetic properties of normal, variant, and .gamma.-carboxyglutamic acid modified human factor IX and factor IXa
ME Jones, MJ Griffith, DM Monroe, HR Roberts, BR Lentz |
Biochemistry | 1985 |